Department of Urology, Xiangya Hospital, Central South University, Changsha, PR China.
Department of Anesthesiology, Second Xiangya Hospital, Central South University, Changsha, PR China.
Cell Cycle. 2022 Dec;21(23):2533-2549. doi: 10.1080/15384101.2022.2103898. Epub 2022 Jul 27.
Bladder cancer can range from noninvasive to invasive tumors. When non-muscle invasive bladder cancer (NMIBC) recurs, patients could endure long-term invasive malignancies with a high disease-specific death rate. Immune escape frequently results in tumor development, metastases, unfavorable prognosis, and failure of immunotherapy. Based on the median immune score, this study used ESTIMATE scores to evaluate 411 bladder cancer cases from TCGA-BLCA. Two hundred two ncRNAs were differentially expressed in two groups, where 29 candidates appeared to be associated with the overall survival of bladder cancer patients. LASSO algorithm was performed to establish the risk score model of 13-ncRNA. Risk scores were computed for cases in the training set, validation set, and TCGA-BLCA set; Poor prognosis in cases with higher risk scores was based on the training set, validating set, and TCGA-BLCA set. Among the 13 ncRNAs, IGF2BP2-AS1, MAGF-AS1, ARHGAP5-AS1, and LINC00942 were significantly correlated with the overall survival of bladder cancer patients. Pearson's correlation analysis based on TCGA-BLCA identified 2093, 3107, 386, and 936 mRNAs co-expressed with IGF2BP2-AS1, MAGF-AS1, ARHGAP5-AS1, and LINC00942, respectively. Conclusively, the 13 ncRNA signature exhibited a feasible predictive prognostic value for bladder cancer patients. IGF2BP2-AS1 expression was higher in bladder cancer tissues and significantly correlated to immune-related factors, suggesting that IGF2BP2-AS1 represents a promising immune-related target for treating bladder cancer patients.
膀胱癌可分为非浸润性和浸润性肿瘤。当非肌肉浸润性膀胱癌（NMIBC）复发时，患者可能会长期患有侵袭性恶性肿瘤，疾病特异性死亡率较高。免疫逃逸常导致肿瘤的发展、转移、预后不良和免疫治疗失败。本研究基于中位数免疫评分，使用 ESTIMATE 评分评估了来自 TCGA-BLCA 的 411 例膀胱癌病例。在两组中，有 202 个 ncRNA 差异表达，其中 29 个候选物似乎与膀胱癌患者的总生存率相关。使用 LASSO 算法建立了由 13 个 ncRNA 组成的风险评分模型。计算了病例在训练集、验证集和 TCGA-BLCA 集中的风险评分；基于训练集、验证集和 TCGA-BLCA 集，高风险评分的病例预后较差。在这 13 个 ncRNA 中，IGF2BP2-AS1、MAGF-AS1、ARHGAP5-AS1 和 LINC00942 与膀胱癌患者的总生存率显著相关。基于 TCGA-BLCA 的 Pearson 相关性分析确定了与 IGF2BP2-AS1、MAGF-AS1、ARHGAP5-AS1 和 LINC00942 分别共表达的 2093、3107、386 和 936 个 mRNAs。综上所述，该 13 个 ncRNA 特征可为膀胱癌患者提供可行的预测预后价值。IGF2BP2-AS1 在膀胱癌组织中的表达较高，与免疫相关因素显著相关，表明 IGF2BP2-AS1 可能成为治疗膀胱癌患者的有前途的免疫相关靶点。
